David Leather

1.4k total citations
41 papers, 942 citations indexed

About

David Leather is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Economics and Econometrics. According to data from OpenAlex, David Leather has authored 41 papers receiving a total of 942 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 21 papers in Physiology and 7 papers in Economics and Econometrics. Recurrent topics in David Leather's work include Asthma and respiratory diseases (21 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (18 papers) and Respiratory and Cough-Related Research (14 papers). David Leather is often cited by papers focused on Asthma and respiratory diseases (21 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (18 papers) and Respiratory and Cough-Related Research (14 papers). David Leather collaborates with scholars based in United Kingdom, United States and Germany. David Leather's co-authors include Ashley Woodcock, Nawar Diar Bakerly, John P. New, Jørgen Vestbo, Martin Gibson, Henrik Svedsäter, Adriano Lazzarin, Chloe Orkin, Patrizia Zucchi and José Ramón Arribas and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and BMJ.

In The Last Decade

David Leather

38 papers receiving 925 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Leather United Kingdom 14 368 277 264 193 137 41 942
Janet Shapiro United States 17 120 0.3× 101 0.4× 119 0.5× 113 0.6× 3 0.0× 60 998
June Fabian South Africa 18 49 0.1× 55 0.2× 180 0.7× 244 1.3× 24 0.2× 91 983
A N Phillips United Kingdom 13 59 0.2× 90 0.3× 57 0.2× 143 0.7× 5 0.0× 14 1.2k
Prateeti Khazanie United States 23 200 0.5× 47 0.2× 210 0.8× 128 0.7× 2 0.0× 66 1.8k
Mahmoud U. Sani Nigeria 18 209 0.6× 26 0.1× 194 0.7× 149 0.8× 3 0.0× 76 1.4k
Samar Abd ElHafeez Egypt 16 71 0.2× 37 0.1× 28 0.1× 123 0.6× 5 0.0× 50 834
Hanna Zowall Canada 15 107 0.3× 31 0.1× 54 0.2× 75 0.4× 4 0.0× 26 1.1k
Abdel G. Babiker United Kingdom 16 31 0.1× 47 0.2× 110 0.4× 373 1.9× 3 0.0× 37 894
Samuel Ajayi Nigeria 14 66 0.2× 20 0.1× 53 0.2× 261 1.4× 50 0.4× 63 727
Hélène Chappuy France 19 84 0.2× 31 0.1× 125 0.5× 287 1.5× 3 0.0× 57 950

Countries citing papers authored by David Leather

Since Specialization
Citations

This map shows the geographic impact of David Leather's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Leather with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Leather more than expected).

Fields of papers citing papers by David Leather

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Leather. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Leather. The network helps show where David Leather may publish in the future.

Co-authorship network of co-authors of David Leather

This figure shows the co-authorship network connecting the top 25 collaborators of David Leather. A scholar is included among the top collaborators of David Leather based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Leather. David Leather is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woodcock, Ashley, Christer Janson, Lucy Frith, et al.. (2022). Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 77(12). 1187–1192. 59 indexed citations
2.
Agustí, Àlvar, Neil Barnes, Álvaro A. Cruz, et al.. (2021). Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine. 187. 106572–106572. 42 indexed citations
3.
Crawford, Rebecca J., Ann‐Louise Caress, Sheila McCorkindale, et al.. (2020). Patient and healthcare professional experiences of the Salford Lung Studies: qualitative insights for future effectiveness trials. Trials. 21(1). 1 indexed citations
4.
Leather, David, Rupert Jones, Ashley Woodcock, et al.. (2020). Real-World Data and Randomised Controlled Trials: The Salford Lung Study. Advances in Therapy. 37(3). 977–997. 9 indexed citations
5.
Fletcher, Monica, Ioanna Tsiligianni, Janwillem Kocks, et al.. (2020). Improving primary care management of asthma: do we know what really works?. npj Primary Care Respiratory Medicine. 30(1). 29–29. 27 indexed citations
6.
Jones, Rupert, Andy Nicholls, Nawar Diar Bakerly, et al.. (2020). Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies. ERJ Open Research. 6(1). 193–2019. 4 indexed citations
7.
8.
Doward, Lynda, Henrik Svedsäter, Diane Whalley, et al.. (2019). A descriptive follow-up interview study assessing patient-centred outcomes: Salford Lung Study in Asthma (SLS Asthma). npj Primary Care Respiratory Medicine. 29(1). 31–31. 1 indexed citations
9.
Whalley, Diane, Henrik Svedsäter, Lynda Doward, et al.. (2019). Follow-up interviews from The Salford Lung Study (COPD) and analyses per treatment and exacerbations. npj Primary Care Respiratory Medicine. 29(1). 20–20. 4 indexed citations
10.
Svedsäter, Henrik, Rupert Jones, Nick Bosanquet, et al.. (2018). Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respiratory Medicine. 141. 198–206. 14 indexed citations
11.
Woodcock, Ashley, I. Boucot, David Leather, et al.. (2018). Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. European Respiratory Journal. 51(2). 1701531–1701531. 27 indexed citations
12.
Svedsäter, Henrik, David Leather, Terence J. Robinson, et al.. (2017). Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys. Respiratory Medicine. 132. 76–83. 12 indexed citations
13.
Kerwin, Edward, Neil Barnes, M.R.J. Gibbs, et al.. (2017). Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms: Post hoc analyses of three randomized controlled trials. Journal of Asthma. 55(8). 890–897. 1 indexed citations
14.
Doward, Lynda, Henrik Svedsäter, Diane Whalley, et al.. (2017). Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes. npj Primary Care Respiratory Medicine. 27(1). 66–66. 13 indexed citations
15.
Vestbo, Jørgen, David Leather, Nawar Diar Bakerly, et al.. (2016). Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice. New England Journal of Medicine. 375(13). 1253–1260. 138 indexed citations
16.
Svedsäter, Henrik, Lucy Frith, David Leather, et al.. (2016). Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy. PubMed. 2(1). 4–4. 10 indexed citations
17.
Bakerly, Nawar Diar, Ashley Woodcock, John P. New, et al.. (2015). The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. Respiratory Research. 16(1). 101–101. 30 indexed citations
18.
New, John P., Nawar Diar Bakerly, David Leather, & Ashley Woodcock. (2014). Obtaining real-world evidence: the Salford Lung Study. Thorax. 69(12). 1152–1154. 66 indexed citations
19.
Gruffydd‐Jones, Kevin, Steve Holmes, Péter Kardos, et al.. (2013). Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled trial. Primary Care Respiratory Journal. 22(1). 37–43. 19 indexed citations
20.
Stellbrink, Hans‐Jürgen, Chloe Orkin, José Ramón Arribas, et al.. (2010). Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study. Clinical Infectious Diseases. 51(8). 963–972. 315 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janet Shapiro Breakdown of academic impact, for papers by June Fabian Breakdown of academic impact, for papers by A N Phillips Breakdown of academic impact, for papers by Prateeti Khazanie Breakdown of academic impact, for papers by Mahmoud U. Sani Breakdown of academic impact, for papers by Samar Abd ElHafeez Breakdown of academic impact, for papers by Hanna Zowall Breakdown of academic impact, for papers by Abdel G. Babiker Breakdown of academic impact, for papers by Samuel Ajayi Breakdown of academic impact, for papers by Hélène Chappuy
Rankless by CCL
2026